Multiple-dose Pharmacokinetics Study of "SYN006 HFA MDI" Administered Orally to Healthy Volunteers

Exclusion Criteria

• •History of drug or alcohol abuse within the past year.
• •Medical history of severe drug allergy or sensitivity to analogous drug.
• •Evidence of acute or chronic diseases or having undergone surgery from 4 weeks prior to Period I dosing.
• •Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary or gastrointestinal pathology. Creatinine \> 2UNL (upper normal limit); Liver enzymes \> 2UNL; Total bilirubin \> 2UNL.
• •Planned vaccination during the time course of the study.
• •Taking any clinical investigation drug from 2 months prior to Period I dosing.
• •Use of any medication, including herb medicine from 4 weeks before dosing.
• •Donation of 500mL of blood in the past 3 months prior to dosing or donation of 250mL of blood in the past 2 months prior to dosing.
• •A positive Hepatitis B surface antigen or positive Hepatitis C antibody result.
• •A positive test for HIV antibody.
• •In screening subjects will be given training to ensure that subjects are able to correctly use the investigational products. If the subjects, the use of the investigational products lack of proficiency will not be included in this study.
• •Students of National Defense Medical Center.
• •For female subjects, if they meet any of the following criteria:
• •1. Lactating women
• •2. Positive pregnancy test (urine) at screening, or prior to dosing
• •3. Do not use adequate contraception during the study
• •4. Women taking oral contraceptives